Skip to main content
. 2014 Jul 15;4(7):e005039. doi: 10.1136/bmjopen-2014-005039

Table 4.

Secondary outcomes

Study ID| TRM after MSD-HSCT*† Graft failure after MSD-HSCT* GVHD after MSD-HSCT* No response to IST* Relapse at 5 years after IST*
Bayever et al20 20% (7 of 35) 3% (1 of 35) 51% (17 of 33) 64% (14 of 22) 12.5% (1 of 8)
Führer et al22 NR NR NR NR NR
Gratwohl et al22 42% (8 of 19) 16% (3 of 19) 26% (5 of 19) 15% (2 of 13) NR

*In parenthesis: number of affected of number of evaluable patients.

†Treatment-related mortality was not reported for IST.

GVHD, graft-versus-host disease; IST, immunosuppressive therapy including ciclosporin and/or antithymocyte or antilymphocyte globulin; MSD-HSCT, first-line allogeneic haematopoietic stem cell transplantation from HLA-matched sibling donor; NR, not reported; TRM, treatment-related mortality.